BioTuesdays

Tag - Robert Hazlett

Aura Biosciences

Analysts start AURA Biosciences at OP, buy

Analysts for SVB Leerink and BTIG initiated coverage of AURA Biosciences (NASDAQ:AURA) with “outperform” and “buy” ratings and price targets of $40 and $38, respectively. The stock closed at $19.82 on Nov. 22. AURA is a...

CTIBiopharmaLogo

BTIG starts CTI Biopharma at buy; PT $7

BTIG initiated coverage of CTI Biopharma (NASDAQ:CTIC) with a “buy” rating and price target of $7. The stock closed at $2.80 on Aug. 6. CTI is a biotechnology company engaged in the development of therapeutics for blood...

Verastem

BTIG ups Verastem to buy from neutral; PT $8

BTIG upgraded Verastem (NASDAQ:VSTM) to “buy” from “neutral” with a new price target of $8, citing a breakthrough designation from the FDA for its KRAS-focused combination therapy of VS-6766 with defactinib for all...

Seelos Therapeutics Logo

BTIG starts Seelos Therapeutics at buy; PT $14

BTIG initiated coverage of Seelos Therapeutics (NASDAQ:SEEL) with a “buy” rating and $14 price target. The stock closed at $3.04 on March 11. Seelos’ lead clinical candidate, SLS-002, is an intranasally delivered...

BTIG ups MannKind PT to $8 from $4

BTIG raised its price target for MannKind (NASDAQ:MNKD) to $8 from $4, citing a recent meeting with MannKind CEO, Michael Castagna, to hear an extensive discussion on Technosphere and Tyvaso DPI expansion, among other...

Prothena

BTIG ups Prothena to buy from neutral; PT $29

BTIG upgraded Prothena (NASDAQ:PRTA) to “buy” from “neutral” with a new PT of $29, citing meaningful progress of multiple clinical assets and with the potential for more promising opportunities to emerge near term. The...

Zosano Logo

BTIG cuts Zosano Pharma PT to $2 from $7

BTIG slashed the price target for Zosano Pharma (NASDAQ:ZSAN) to $2 from $7, citing a complete response letter about the NDA for Qtrypta, a transdermal microneedle system form of zolmitriptan in development for acute...

Axsome Therapeutics

BTIG ups Axsome Therapeutics PT to $48 from $25

BTIG raised its price target for Axsome Therapeutics (NASDAQ:AXSM) to $48 from $25 after the company announced positive Phase 2 data for its AXS-12 drug candidate for the treatment of cataplexy and excessive daytime...

NextCure

BTIG starts NextCure at buy; PT $61

BTIG initiated coverage of NextCure (NASDAQ:NXTC) with a “buy” rating and $61 price target. The stock closed at $39.84 on Nov. 25. NextCure is developing first‐in‐class medicines to treat cancer and other immune‐related...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.